Free Trial

Cara Therapeutics (TVRD) Competitors

$29.00 -0.86 (-2.88%)
As of 05/30/2025 04:00 PM Eastern

TVRD vs. AUPH, MLYS, CVAC, PAHC, RCUS, COLL, WVE, SYRE, SNDX, and ARDX

Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Aurinia Pharmaceuticals (AUPH), Mineralys Therapeutics (MLYS), CureVac (CVAC), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Wave Life Sciences (WVE), Spyre Therapeutics (SYRE), Syndax Pharmaceuticals (SNDX), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

Cara Therapeutics vs.

Cara Therapeutics (NASDAQ:TVRD) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Aurinia Pharmaceuticals received 576 more outperform votes than Cara Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 50.00% of users gave Cara Therapeutics an outperform vote.

CompanyUnderperformOutperform
Cara TherapeuticsOutperform Votes
1
50.00%
Underperform Votes
1
50.00%
Aurinia PharmaceuticalsOutperform Votes
577
73.41%
Underperform Votes
209
26.59%

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Cara Therapeutics. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 4 mentions for Cara Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.50 beat Cara Therapeutics' score of 0.58 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cara Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aurinia Pharmaceuticals
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cara Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cara Therapeutics has higher earnings, but lower revenue than Aurinia Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara TherapeuticsN/AN/AN/AN/AN/A
Aurinia Pharmaceuticals$247.30M4.29-$78.02M$0.2828.07

Cara Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 124.14%. Aurinia Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 46.31%. Given Cara Therapeutics' higher possible upside, equities research analysts clearly believe Cara Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aurinia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cara Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Cara Therapeutics' return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara TherapeuticsN/A N/A N/A
Aurinia Pharmaceuticals -10.23%-4.41%-3.07%

Summary

Aurinia Pharmaceuticals beats Cara Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Cara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVRD vs. The Competition

MetricCara Therapeutics IndustryManufacturing SectorNASDAQ Exchange
Market Cap$271.47M$2.78B$2.01B$8.40B
Dividend YieldN/A13.01%2.64%4.17%
P/E RatioN/A11.7522.6619.77
Price / SalesN/A1,529,289.7156.90134.17
Price / CashN/A15.8051.7234.64
Price / BookN/A3.152.054.50
Net IncomeN/A$81.02M-$330.96M$248.20M
7 Day Performance-0.31%0.42%1.00%0.99%
1 Month PerformanceN/A4.37%6.87%8.02%
1 Year PerformanceN/A4.26%13.97%8.86%

Cara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVRD
Cara Therapeutics
N/A$29.00
-2.9%
$65.00
+124.1%
N/A$271.47MN/A0.0080High Trading Volume
AUPH
Aurinia Pharmaceuticals
3.4108 of 5 stars
$7.86
-1.6%
$11.50
+46.3%
+46.1%$1.06B$247.30M-52.40300Positive News
MLYS
Mineralys Therapeutics
2.968 of 5 stars
$15.73
+0.4%
$38.00
+141.6%
+26.7%$1.03BN/A-4.3228Positive News
Gap Down
High Trading Volume
CVAC
CureVac
3.9461 of 5 stars
$4.53
-2.2%
$11.00
+142.8%
+20.2%$1.02B$523.70M8.24880News Coverage
Analyst Forecast
PAHC
Phibro Animal Health
3.6852 of 5 stars
$24.58
-0.3%
$20.00
-18.6%
+38.1%$996.33M$1.19B51.211,860Positive News
RCUS
Arcus Biosciences
2.5011 of 5 stars
$8.98
-5.6%
$25.67
+185.8%
-39.9%$950.85M$141M-2.85500Positive News
Short Interest ↑
COLL
Collegium Pharmaceutical
4.0401 of 5 stars
$29.39
+0.7%
$43.80
+49.0%
-9.4%$944.36M$664.28M12.67210Positive News
WVE
Wave Life Sciences
4.3576 of 5 stars
$6.08
-2.6%
$21.17
+248.1%
-1.5%$937.14M$104.94M-5.48240Positive News
SYRE
Spyre Therapeutics
2.4763 of 5 stars
$15.25
-1.9%
$53.40
+250.2%
-55.2%$919.21M$890,000.00-2.0473News Coverage
Positive News
SNDX
Syndax Pharmaceuticals
3.866 of 5 stars
$10.57
-0.5%
$35.91
+239.7%
-45.2%$909.52M$43.72M-2.91110Positive News
ARDX
Ardelyx
4.6125 of 5 stars
$3.72
-7.7%
$10.39
+179.3%
-45.1%$890.03M$361.71M-23.2590Gap Down

Related Companies and Tools


This page (NASDAQ:TVRD) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners